HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

duloxetine (Cymbalta)

structure given in first source; RN refers to (+-)-isomer; LY 248686 is the (+)-isomer

Also Known As:

Cymbalta; Eli Lilly brand of duloxetine hydrochloride; LY 227942; LY 248686; LY-227942; LY-248686; LY227942; N-methyl-3-(1-naphthalenyloxy)-2-thiophenepropanamine; N-methyl-3-(1-naphthalenyloxy)-3-(2-thiophene)propanamide; duloxetine ethanedioate (1:1), (+-)-isomer; duloxetine hydrochloride; duloxetine, (+)-isomer; duloxetine, (-)-isomer

Networked: 976 relevant articles (261 outcomes, 348 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Wohlreich, Madelaine M: 47 articles (04/2014 - 01/2004)
2.	Detke, Michael J: 37 articles (03/2011 - 01/2002)
3.	Raskin, Joel: 33 articles (01/2014 - 10/2003)
4.	Mallinckrodt, Craig H: 31 articles (07/2009 - 10/2003)
5.	Wang, Fujun: 24 articles (07/2012 - 06/2005)
6.	Desaiah, Durisala: 23 articles (01/2013 - 12/2005)
7.	Watkin, John G: 22 articles (07/2009 - 01/2004)
8.	Arnold, Lesley M: 21 articles (05/2015 - 09/2004)
9.	Kajdasz, Daniel K: 20 articles (06/2011 - 07/2005)
10.	Chappell, Amy S: 20 articles (06/2011 - 03/2007)

Related Diseases

1.	Pain (Aches) 10/01/2011 - "Quantifiable early improvement in pain during the first 2 weeks of treatment with duloxetine was highly predictive of response or nonresponse after 3 months of treatment. " 01/01/2007 - "The treatment with cymbalta resulted in significant reduction of pain in 90% patients, with full stopping of the syndrome in 10% and marked reduction in 55%. " 02/01/2005 - "Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents." 09/01/2015 - "Duloxetine-treated patients showed significantly greater pain relief compared with placebo-treated patients over the 12-week study period. " 09/01/2015 - "Duloxetine-treated patients showed significantly greater pain relief on 24-h average pain ratings compared with placebo-treated patients each week of the 12-week study period [week 12: least squares (LS) mean change duloxetine: -2.40, placebo: -1.97; LS mean change difference (95% confidence interval) = -0.43 (-0.82, -0.04), p = 0.030]. "
2.	Major Depressive Disorder (Major Depressive Disorders) 11/01/2007 - "Duloxetine demonstrated superior efficacy in the treatment of major depressive disorder, when compared with placebo, regardless of the baseline severity of depressive symptoms, although effect sizes were largest in the most severely depressed patients." 01/01/2011 - "Efficacy of duloxetine on painful physical symptoms in major depressive disorder for patients with clinically significant painful physical symptoms at baseline: a meta-analysis of 11 double-blind, placebo-controlled clinical trials." 01/01/2011 - "To review efficacy of duloxetine for physical symptoms and depressive illness in patients with at least mild to moderate major depressive disorder (MDD; DSM-IV) and clinically significant painful physical symptoms at baseline. " 08/01/2007 - "This was a post hoc analysis to determine whether baseline severity of depression influenced the efficacy of duloxetine in treating major depressive disorder (MDD) and to better characterise the symptom response profile for duloxetine in patients with mild, moderate or more severe depression. " 01/01/2007 - "In placebo-controlled clinical trials, duloxetine has been shown to be effective and well-tolerated in patients with major depressive disorder (MDD). "
3.	Fibromyalgia (Fibrositis) 12/01/2010 - "To investigate the efficacy of flexible dose duloxetine 60-120 mg/day on changes in fibromyalgia (FM) symptoms assessed by the Patient Global Impression of Improvement (PGI-I) scale. " 05/01/2006 - "Duloxetine effective for fibromyalgia in some women." 09/01/2007 - "Duloxetine has been shown to be an effective and safe treatment for many of the symptoms associated with fibromyalgia, particularly for women. " 07/01/2013 - "Clinical trials have demonstrated the analgesic efficacy of duloxetine for PDN and fibromyalgia in addition to improvements in quality-of-life measurements. " 06/01/2011 - "Data were pooled across 12-week treatment periods from 4 randomized, double-blind, placebo-controlled studies designed to evaluate the safety and efficacy of duloxetine for the treatment of fibromyalgia. "
4.	Neuralgia (Stump Neuralgia) 02/01/2008 - "This UK-based economic model suggests that second-line use of duloxetine is a beneficial and cost-effective treatment strategy for diabetic peripheral neuropathic pain." 11/01/2010 - "Although the primary study endpoint was not achieved, the overall observed response pattern suggests the efficacy of duloxetine in the treatment of Chinese patients with diabetic peripheral neuropathic pain. " 10/24/2006 - "This study confirms previous findings that duloxetine at 60 mg QD and 60 mg BID is effective and safe in the management of diabetic peripheral neuropathic pain." 07/01/2005 - "Duloxetine at 60 and 120 mg/d was safe and effective in the management of diabetic peripheral neuropathic pain." 01/01/2009 - "Safety and efficacy of duloxetine in the treatment of diabetic peripheral neuropathic pain in older patients."
5.	Stress Urinary Incontinence 07/01/2007 - "Duloxetine has been shown to be effective in women with stress urinary incontinence (SUI). " 12/01/2009 - "Duloxetine was found safe and effective in the treatment of moderate to severe female stress urinary incontinence (SUI) in controlled clinical trials; complementary data from routine clinical practice are still wanted. " 07/01/2008 - "To assess the maintenance of efficacy of duloxetine beyond 3 months, using data from several long-term, open-label studies, as the efficacy of duloxetine 40-mg twice daily for treating women with stress urinary incontinence (SUI) for up to 3 months has been established in several randomized, placebo-controlled clinical trials. " 11/01/2005 - "The clinical efficacy of duloxetine has consistently been demonstrated in several randomized, double-blind studies in women with moderate-to-severe stress urinary incontinence, but the additional benefit relative to placebo was moderate. " 07/01/2005 - "In clinical trials in women with stress urinary incontinence, duloxetine has demonstrated efficacy in reducing incontinence episodes and increasing quality of life with no serious adverse effects. "

Related Drugs and Biologics

1.	Serotonin (5 Hydroxytryptamine)
2.	Norepinephrine (Noradrenaline)
3.	pregabalin (Lyrica)
4.	venlafaxine (Effexor)
5.	milnacipran (Ixel)
6.	Antidepressive Agents (Antidepressants)
7.	Amitriptyline (Elavil)
8.	Citalopram (Escitalopram)
9.	gabapentin (Neurontin)
10.	Tricyclic Antidepressive Agents (Tricyclic Antidepressants)

Related Therapies and Procedures

1.	Prostatectomy (Retropubic Prostatectomy)
2.	Drug Therapy (Chemotherapy)
3.	Oral Administration
4.	Analgesia
5.	Electric Stimulation Therapy (Electrotherapy)